CXCL9 and CXCL10 bring the heat to tumors

Article Oncology

Phase I Trial Combining Chemokine-Targeting with Loco-Regional Chemoimmunotherapy for Recurrent, Platinum-Sensitive Ovarian Cancer Shows Induction of CXCR3 Ligands and Markers of Type 1 Immunity

Brian Orr et al.

Summary: The purpose of this study was to investigate the safety and modulatory effects on the tumor microenvironment of a novel intraperitoneal chemoimmunotherapy combination in patients with epithelial ovarian cancer. The results showed that this combination therapy was well tolerated and associated with enhanced chemotaxis and function of cytotoxic T lymphocytes.

CLINICAL CANCER RESEARCH (2022)

Add to Collection

Article Immunology

Multiplexed imaging mass cytometry of the chemokine milieus in melanoma characterizes features of the response to immunotherapy

Tobias Hoch et al.

Summary: Intratumoral immune cells play a crucial role in tumor control and antitumor responses during immunotherapy. This study analyzed the chemokine expression and immune infiltration in melanoma using multiplexed mass cytometry-based imaging, and found that tumors lacking immune infiltration had low levels of chemokines, antigen presentation, and markers of inflammation, while infiltrated tumors expressed multiple chemokines.

SCIENCE IMMUNOLOGY (2022)

Add to Collection

Article Oncology

Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma

Antoni Ribas et al.

Summary: In patients with advanced melanoma, combining intratumoral TLR9 agonist vidutolimod with pembrolizumab showed promising clinical activity and manageable safety profile, indicating potential to overcome resistance to PD-1 blockade through IFN response induction.

CANCER DISCOVERY (2021)

Add to Collection

Article Oncology

Immune cell and tumor cell-derived CXCL10 is indicative of immunotherapy response in metastatic melanoma

Robin Reschke et al.

Summary: In human melanoma metastases, CD45(+) cells and Sox10(+) cells are identified as the major cellular sources for CXCL10. CXCL10 within the tumor site serves as a positive prognostic factor for response to immunotherapy, and the use of RNAscope technique is feasible in paraffin tissue. Strategies supporting effector T cell recruitment through the induction of CXCL10 may enhance the efficacy of immunotherapy.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Add to Collection

Article Oncology